Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. Biologic DMARDs and targeted synthetic DMARDs approved.

Published byHendra Darmadi Modified over 5 years ago

Similar presentations

Presentation on theme: "Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. Biologic DMARDs and targeted synthetic DMARDs approved."— Presentation transcript:

1 Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis.
Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. DMARDs, disease-modifying antirheumatic drugs; IFN, interferon; IL,interleukin; IL6R, interleukin 6 receptor; INFγ, interferon γ; JAK-STAT, Janus Kinase/Signal Transducer and Activator of Transcription proteins; mAb, monoclonalantibody; MHC, major histocompatibility complex; mIL6R, membraneinterleukin 6 receptor; sIL-6R, soluble interleukin 6 receptor; TCR, T cellreceptor; TNF, tumor necrosis factor. Katerina Chatzidionysiou, and Petros P Sfikakis RMD Open 2019;5:e000993 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. Biologic DMARDs and targeted synthetic DMARDs approved."

Similar presentations

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.
Rheumatoid arthritis The Lancet

Rheumatoid arthritis The Lancet
My Treatment Approach to Rheumatoid Arthritis

My Treatment Approach to Rheumatoid Arthritis
Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
Correlations of CD68, CD21, CD3, CD20 and CD117 immunohistochemical staining between paired synovial tissue (ST) and colonic mucosa (CM) biopsies of patients.

Correlations of CD68, CD21, CD3, CD20 and CD117 immunohistochemical staining between paired synovial tissue (ST) and colonic mucosa (CM) biopsies of patients.
What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy donors and in patients with RA in remission?

What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy donors and in patients with RA in remission?
Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
My Treatment Approach to Rheumatoid Arthritis

My Treatment Approach to Rheumatoid Arthritis
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
JAK inhibitors in dermatology: The promise of a new drug class

JAK inhibitors in dermatology: The promise of a new drug class
Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.
Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during.

Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response

Similar presentations

Ads by Google